Autoimmune encephalitis

This trial tests a therapy called CTX112 in adults with severe neurologic autoimmune diseases, including progressive multiple sclerosis, neuromyelitis optica, and stiff-person syndrome. CTX112 uses donor T cells edited with CRISPR to target and deplete B cells, which are thought …

This trial is testing an experimental therapy called CTA313, which uses engineered immune cells (CAR T cells) to potentially reset the immune system in people with active autoimmune diseases. The study will include adults aged 18 to 75 with systemic lupus erythematosus, progressi…

This early-phase trial will test a new treatment called QT-019C in up to 15 adults with relapsed or refractory neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica, and myasthenia gravis. The treatment uses donor-derived CAR T-cells that target two…

This early-stage trial is testing a new treatment called C-CAR168, which uses a patient's own immune cells modified to attack harmful cells in the body. It is for 15 adults with multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person syndrome that have …

This early-stage study tests a new cell therapy called HY001N in 15 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The main goal is to check safety and side effects, while also looking for signs of improvement in disability…

This study will follow 1,550 adults with various neurological autoimmune diseases—like multiple sclerosis, myasthenia gravis, and autoimmune encephalitis—to see how these conditions progress and respond to treatments in everyday medical practice. Researchers will measure disabili…